Session

Pharmaceutical and Natural Sciences

Description

An analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes collected from the patients worldwide has identified mutations in the virus that could aid in drug and vaccine development. The researchers found that the virus’s genetic diversity in most countries is similar to what it is globally, suggesting that it was introduced repeatedly by many infected people in each country rather than by a “patient zero.” The genetic analysis found 198 mutations that have occurred more than once. “Mutations in themselves are not a bad thing it is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected. Several factors, including pharmacogenetics, it is possible to contribute to inter-individual variability in drug response. However, till today little is known about the host genetics interaction with infection and COVID-19 progression. To understand the role of host gene, we review the current literature, aggregate readily available genetic resources, and provide some updated analysis relevant to COVID-19 and associated phenotypes.

Keywords:

SARS-CoV-2, gene information, genetic variability, gene expression, gene polymorphism

Session Chair

Valon Ejupi

Session Co-Chair

Shpend Dragusha

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-437-96-7

First Page

25

Last Page

32

Location

Lipjan, Kosovo

Start Date

31-10-2020 10:45 AM

End Date

31-10-2020 12:15 PM

DOI

10.33107/ubt-ic.2020.444

Download

Share

COinS
 
Oct 31st, 10:45 AM Oct 31st, 12:15 PM

Pharmacogenetics- gene and SARS-COVID 19 Medication

Lipjan, Kosovo

An analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes collected from the patients worldwide has identified mutations in the virus that could aid in drug and vaccine development. The researchers found that the virus’s genetic diversity in most countries is similar to what it is globally, suggesting that it was introduced repeatedly by many infected people in each country rather than by a “patient zero.” The genetic analysis found 198 mutations that have occurred more than once. “Mutations in themselves are not a bad thing it is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected. Several factors, including pharmacogenetics, it is possible to contribute to inter-individual variability in drug response. However, till today little is known about the host genetics interaction with infection and COVID-19 progression. To understand the role of host gene, we review the current literature, aggregate readily available genetic resources, and provide some updated analysis relevant to COVID-19 and associated phenotypes.